Pall’s Nanosep Centrifugal Device Offers High Nucleic Acid Binding Capacity

Article

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter-04-01-2020
Volume 15
Issue 4
Pages: 12

The new NAB Nanosep device provides increased binding capacity.

Pall’s newly introduced nucleic acid binding (NAB) Nanosep centrifugal device provides increased binding capacity through an innovative dual-layer, silica-based quartz glass fiber membrane. It can be used for applications that require highly efficient nucleic acid isolation.

Researchers using this multipurpose NAB Nanosep device can purify plasmid DNA, genomic DNA, or total RNA from a variety of starting materials. The centrifugal device can recover from 10,000 to 50 base pairs, allowing users to analyze the widest range of nucleic acid fragments in a single spin device, Pall announced in a March 11, 2020 press release.

The device offers flexibility and rapid processing without sacrificing yield or quality of the nucleic acids. Its double-layer membrane can isolate nucleic acids with yields high enough to allow multiple downstream applications, which can save time and cost by eliminating the need to process additional samples. The device has ultrasonically welded seals to prevent bypass contamination or seal failure and fits standard centrifuge rotors that accept 1.5-mL tubes.

The NAB Nanosep device is ideal for applications in the following workflows:

  • Purified plasmid DNA: restriction digest, cloning, and Sanger sequencing

  • Purified genomic DNA: quantitative polymerase chain reaction and next-generation sequencing

  • Purified total RNA: Reverse transcription polymerase chain reaction and cDNA library construction

Source: Pall

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Related Content